FSTL3, His, Human
FSTL3, His, Human

Immobilized FSTL3, His, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-FSTL3 Antibody, hFc Tag with the EC50 of 2.7 ng/ml determined by ELISA.

FSTL3, His, Human

FSTL3, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

FSTL3, His, Human

Measured by its ability to neutralize Activin-mediated inhibition on MPC11 cell proliferation. The ED50 for this effect is typically 5-25 ng/mL in the presence of 7.5 ng/mL rhActivin A.

FSTL3, His, Human

Immobilized Human Activin A, No Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for FSTL3, His, Human, His Tag with the EC50 of 7.6ng/ml determined by ELISA.

FSTL3, His, Human

Follistatin-like 3 (FSTL3) is a novel cytokine that regulates insulin sensitivity and counteracts activin/myostatin signalling. In the present study, regulation of FSTL3 in renal dysfunction was investigated in both human chronic kidney disease (CKD) and acute kidney dysfunction (AKD). Furthermore, mFSTL3 expression was analysed in insulin-sensitive tissues in a mouse model of CKD.
Z05323
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
FSTL3 (Met27-Val263)
Accession # O95633-1		 His
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized FSTL3, His, Human at 0.5μg/ml (100μl/Well) on the plate can bind Anti­FSTL3 Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 26.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 35-40 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • FSTL3, His, Human
    • FSTL3, His, Human

    Immobilized FSTL3, His, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-FSTL3 Antibody, hFc Tag with the EC50 of 2.7 ng/ml determined by ELISA.

  • FSTL3, His, Human
    • FSTL3, His, Human

    FSTL3, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • FSTL3, His, Human
    • FSTL3, His, Human

    Measured by its ability to neutralize Activin-mediated inhibition on MPC11 cell proliferation. The ED50 for this effect is typically 5-25 ng/mL in the presence of 7.5 ng/mL rhActivin A.

  • FSTL3, His, Human
    • FSTL3, His, Human

    Immobilized Human Activin A, No Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for FSTL3, His, Human, His Tag with the EC50 of 7.6ng/ml determined by ELISA.


Background
Target Background Follistatin-like 3 (FSTL3) is a novel cytokine that regulates insulin sensitivity and counteracts activin/myostatin signalling. In the present study, regulation of FSTL3 in renal dysfunction was investigated in both human chronic kidney disease (CKD) and acute kidney dysfunction (AKD). Furthermore, mFSTL3 expression was analysed in insulin-sensitive tissues in a mouse model of CKD.
Synonyms FLRG; FLRGFSRP; Follistatin-like 3; FSTL3

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.